publication venue for
- Pathophysiology, diagnosis, and management of hepatic encephalopathy. 22:319-326. 2014
- Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?. 21:125-127. 2013
- The pharmacological modulation of allergen-induced asthma. 21:113-124. 2013
- The end of evidence-based medicine?. 20:187-193. 2012
- Commentary Re: Botox Article by Berger & Knoll IPH 19(5):243–244 on “The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis”. 20:51-51. 2012
- Drug-resistant tuberculosis: an insurmountable epidemic?. 19:131-137. 2011
- Paul-Peter Tak (ed): New Therapeutic Targets in Rheumatoid Arthritis (Series: PIR—Progress in Inflammation Research). 19:53-54. 2011
- The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. 19:21-34. 2011
- Concerning: “The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy” by Peter O. Behan and Abhijit Chaudhuri. 18:263-263. 2010
- Analgesic targets: today and tomorrow. 17:151-161. 2009
- Therapeutic transcranial magnetic stimulation in migraine and its implications for a neuroinflammatory hypothesis. 17:68-75. 2009
- Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. 11:337-354. 2003
- Coronary artery disease, inflammation and the ghost of John Hunter. 11:195-201. 2003
- A clinician’s view of strategies for preventing NSAID-induced gastrointestinal ulcers. 4:17-30. 1996
- Effects of non-steroidal anti-inflammatory drugs on prostaglandin h synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture. 3:299-310. 1995